Contemporary Clinical Trials - McMaster Experts

publication venue for

A randomized trial of opinion leader endorsement in a survey of orthopaedic surgeons 2003
An assessment of potential unblinding in a clinical trial 2003
Evaluating the validity of record linkages in the ascertainment of vital status for post-trial follow-up of a heart failure clinical trial 2003
Industry funding and authors' conclusions in medical and surgical randomized trials 2003
Study to prospectively evaluate reamed intramedullary nails in tibial shaft fractures (SPRINT) 2003
Design and implementation of the NHLBI and the VA cooperative studies program collaborative study, “trial to evaluate the effect of digitalis on motality in heart failure” 1992
Eligible-non-randomized patients: Their impact on generalizability 1992
Health care directives in the elderly and health care utilization 1992
Impact of a randomized trial on transfusion practice in orthopedic surgery 1992
Methodological and ethical issues in a series of exploratory multiple crossover double-blind studies in individual patients with dementia to assess the efficacy and safety of CGS 5649B 1992
Design issues in the measurement of quality of life in a trial of two prenatal diagnostic technologies: Genetic amniocentesis and chorionic villi sampling 1990
Efficacy versus intent-to-treat analysis in the canadian American ticlopidine study 1990
Must the evaluator be blinded? 1990
·57 Crossover trials in chronic disease 1990
·58 Methodologic issues in a randomized trial to evaluate the effects of omega-3 polyunsaturated fatty acids and low-molecular-weight heparin on restenosis following percutaneous transluminal coronary angioplasty 1990
·P-15 The operation of a central adjudication committee and its effect of the validity of the assessment of treatment benefit 1990
·P-27 Systems of logging exclusions in multicenter clinical trials 1990
·P-53 Methodological guidelines for randomized clinical trials of surgical procedures 1990
Criteria for bleeding events in a heart valve replacement trial 1989
Monitoring compliance and contamination in a chemoprevention trial 1989
Permanent discontinuation of study drugs in long-term clinical trials 1989
Quality of life in stage 2 breast cancer patients measured by a time trade off method 1989
ANALYTIC ASPECTS OF SINGLE-SUBJECT TRIALS 1988
Design issues in trials of smoking cessation 1988
Differences in methodology betweem randomized trials comparing treatments and those evaluating diagnostic tests 1988
MAINTAINING BLINDNESS IN TRIALS INVOLVING ORAL ANTICOAGULANTS 1988
The use of N of 1 RCTs in drug development 1988
The use of an FDA-NDA database to assess the risk of exposing patients with chronic stable angina to placebo-controlled trials 1988
A COMPARISON OF LIKERT AND VISUAL ANALOG SCALES FOR MEASURING CHANGE IN FUNCTION 1987
CONDUCTING CROSSOVER TRIALS WHEN PATIENTS ARE UNSTABLE - AN APPROACH, AND AN EXAMPLE 1987
Comparison of quality of life instruments in a setting of a clinical trial 1987
A comparison of functional status measures in chronic lung disease: Data from a randomized control trial 1986
Prerandomization adherence aids for clinical trials 1986
Surrogate endpoint use in cardiovascular clinical trials 1986
Assessing disease-specific quality of life in clinical trials 1985
Comparisons of cause of death verification methods and costs in the lipid research clinics program follow-up study 1985
Current treatments of cardiovascular diseases are unlikely to produce more than moderate reductions in mortality 1985
Data management issues in the international multicenter study of general anesthesia 1985
Single-subject designs 1985
Surrogate endpoints in clinical trials 1985
Logistics of double-blinding a randomized trial of intravenous vs. subcutaneous heparin for the treatment of venous thrombosis 1984
AN INTERNATIONAL MULTICENTER TRIAL OF GENERAL-ANESTHESIA 1983
PATIENT COMPLIANCE AND THE DESIGN AND EXECUTION OF CLINICAL-TRIALS 1983
Assessing the effectiveness of screening programs 1982
Relative efficiency in the analysis of survival data 1982
Stopping rules for long-term clinical trials 1980
Protocol for a randomized clinical trial to confirm the effectiveness of online guided self-help family-based treatment for adolescent anorexia nervosa. 144:107618-107618. 2024
Recruiting families using social media versus pediatric obesity clinics: A secondary analysis of the Aim2Be RCT. 133:107322-107322. 2023
Healthcare systems data in the context of clinical trials – A comparison of cardiovascular data from a clinical trial dataset with routinely collected data. 128:107162-107162. 2023
Machine learning for detecting centre-level irregularities in randomized controlled trials: A pilot study. 122:106963-106963. 2022
Women's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment. 115:106714-106714. 2022
Three week compared to seven week run-in period length and the assessment of pre-randomization adherence: A study within a trial. 107:106466-106466. 2021
Moving forward in clinical research with master protocols. 106:106438-106438. 2021
Reporting and design of randomized controlled trials for COVID-19: A systematic review. 101:106239-106239. 2021
Fragility of clinical trials across research fields: A synthesis of methodological reviews. 97:106151-106151. 2020
Agreement in reporting between trial publications and current clinical trial registry in high impact journals: A methodological review. 65:144-150. 2018
Protocol for the MATCH study (Mindfulness and Tai Chi for cancer health): A preference-based multi-site randomized comparative effectiveness trial (CET) of Mindfulness-Based Cancer Recovery (MBCR) vs. Tai Chi/Qigong (TCQ) for cancer survivors. 59:64-76. 2017
Are current standards of reporting quality for clinical trials sufficient in addressing important sources of bias?. 45:2-7. 2015
The ‘Expanded HIV care in opioid substitution treatment’ (EHOST) cluster-randomized, stepped-wedge trial: A study protocol. 45:201-209. 2015
The keys to healthy family child care homes intervention: Study design and rationale. 40:81-89. 2015
Improvement in the quality of abstracts in major clinical journals since CONSORT extension for abstracts: A systematic review. 38:245-250. 2014
Designing and implementing a comparative effectiveness study of two strategies for delivering high quality CHD prevention: Methods and participant characteristics for the Heart to Health study. 36:394-405. 2013
Study design of ASPirin in Reducing Events in the Elderly (ASPREE): A randomized, controlled trial. 36:555-564. 2013
Functional Dyspepsia Treatment Trial (FDTT): A double-blind, randomized, placebo-controlled trial of antidepressants in functional dyspepsia, evaluating symptoms, psychopathology, pathophysiology and pharmacogenetics. 33:523-533. 2012
Competing events in patients with malignant disease who are at risk for recurrent venous thromboembolism. 32:829-833. 2011
A community-based clinical trial of Intra-Venous zOledRonic acid once Yearly in comparison to oral bisphosphonates in postmenopausal women with osteoporosis: The IVORY trial. 32:741-746. 2011
Data withdrawal in randomized controlled trials: Defining the problem and proposing solutions. 32:318-322. 2011
Design and methods of the MAINTAIN study: A randomized controlled clinical trial of micronutrient and antioxidant supplementation in untreated HIV infection. 31:604-611. 2010
The “parallel-cohort RCT”: Novel design aspects and application in the Kids-DOTT trial of pediatric venous thromboembolism. 31:131-133. 2010
A small p-value from an observed data is not evidence of adequate power for future similar-sized studies: A cautionary note. 30:155-157. 2009
Identifying subpopulations for subgroup analysis in a longitudinal clinical trial. 29:817-822. 2008
Strategies to enhance patient recruitment and retention in research involving patients with a first episode of mental illness. 29:862-866. 2008
TEACH: Trial of Education And Compliance in Heart dysfunction chronic disease and heart failure (HF) as an increasing problem. 29:905-918. 2008
Epidemiology and reporting of randomized trials employing re-randomization of patient groups: A systematic survey. 28:268-275. 2007
Estimating per patient funding for cancer clinical trials: An Ontario based survey. 26:421-429. 2005
Pre-trial evaluation of the potential for unblinding in drug trials: A prototype example. 26:459-468. 2005
The quality of randomized trial reporting in leading medical journals since the revised CONSORT statement. 26:480-487. 2005
Adjustment for baseline measurement error in randomized controlled trials induces bias. 25:408-416. 2004
Evaluation of outcome and cost-effectiveness using an FDG PET-guided approach to management of patients with coronary disease and severe left ventricular dysfunction (PARR-2): rationale, design, and methods. 24:776-794. 2003
Lessons learned from the DIG trial. 24:S316-S326. 2003
Limiting loss to follow-up in a multicenter randomized trial in orthopedic surgery. 24:719-725. 2003
Limiting loss to follow-up in a multicenter randomized trial in orthopedic surgery. 24:719-725. 2003
Overview of the DIG trial. 24:S269-S276. 2003
The role of the data coordinating center in the DIG trial. 24:S277-S288. 2003
The role of the data coordinating center in the IRB review and approval process: the DIG trial experience. 24:S306-S315. 2003
The role of the pharmacy coordinating center in the DIG trial. 24:S289-S297. 2003
Termination of a randomized controlled trial of two vasectomy techniques. 24:78-84. 2003
The reporting of methodological factors in randomized controlled trials and the association with a journal policy to promote adherence to the Consolidated Standards of Reporting Trials (CONSORT) checklist. 23:380-388. 2002
Letter to the editor. 22:687-688. 2001
Design and Analytic Considerations in Determining the Cost-Effectiveness of Early Intervention in Asthma from a Multinational Clinical Trial. 22:420-437. 2001
The Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) Study. 22:405-419. 2001
Analysis, Sample Size, and Power for Estimating Incremental Net Health Benefit from Clinical Trial Data. 22:228-237. 2001
Cumulating evidence from randomized trials: Utilizing sequential monitoring boundaries for cumulative meta-analysis. 18:580-593. 1997
Introduction. 18:477-477. 1997
Meta-analysis of randomized trials: Looking back and looking ahead. 18:594-601. 1997
Strengths and limitations of meta-analysis: Larger studies may be more reliable. 18:568-579. 1997
91 Design of the randomized evaluation of strategies for left ventricular dysfunction (resolvd) pilot study: A trial of combination neurohormonal blockade in patients with congestive heart failure. 18:S98-S98. 1997
Outcome assessment for clinical trials: How many adjudicators do we need?. 18:27-42. 1997
Benefit-risk ratios in the assessment of the clinical evidence of a new therapy. 18:121-130. 1997
Rationale, design, implementation, and baseline characteristics of patients in the dig trial: A large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. 17:77-97. 1996
38A Benefit-risk ratios in the assessment of the clinical evidence of a new therapy. 16:54S-54S. 1995
P47 Randomized controlled trial of aerobic plus resistance exercise training in patients with congestive heart failure. 16:99S-99S. 1995
P81 A trial evaluating the home treatment of patients with acute proximal deep vein thrombosis (DVT). 16:118S-118S. 1995
Power function arguments in support of an alternative approach for analyzing management trials. 15:211-219. 1994
A questionnaire to measure morbidity in patients receiving radiation therapy for head and neck cancer. 13:389-389. 1992
Quality of life assessment: Patient compliance with questionnaire completion. 12:708-709. 1991
Simultaneous randomization to multiple dose levels and an active comparator as a means of determining the minimal effective dose of an investigational agent. 12:696-696. 1991
A comparison of evaluative indices of quality of life and cognitive function in hemodialysis patients. 12:S159-S167. 1991
Current quality-of-life research challenges in arthritis relevant to the issue of clinical significance. 12:S217-S225. 1991
Interpreting changes in quality-of-life score in N of 1 randomized trials. 12:S226-S233. 1991
Introduction. 12:S79-S80. 1991
Issues in quality-of-life measurement in clinical trials. 12:S81-S90. 1991
Methodologic challenges in the development of utility measures of health-related quality of life in rheumatoid arthritis. 12:S118-S128. 1991
Postscript. 12:S266-S269. 1991
The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin. 12:S168-S179. 1991
N of 1 randomized trials for investigating new drugs. 11:88-100. 1990
A comparison of seven-point and visual analogue scales. 11:43-51. 1990
Measurement of health status. 10:407-415. 1989
Comparisons of cause of death verification methods and costs in the lipid research clinics program mortality follow-up study. 10:167-187. 1989
The likelihood ratio versus the p value in meta-analysis: Where is the evidence?. 10:205-208. 1989
Patient compliance and the conduct and interpretation of therapeutic trials. 8:12-19. 1987
Using baseline measurements in the two-period crossover clinical trial. 7:282-289. 1986
Use of stable isotopes to determine compliance. 5:573-575. 1984
Clinical trials as diagnostic tests. 5:107-113. 1984
Economic analysis and clinical trials. 5:115-128. 1984

Contemporary Clinical Trials Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)